In vivo recovery of factor VIII and factor IX:: intra- and interindividual variance in a clinical setting

被引:59
作者
Bjorkman, S.
Folkesson, A.
Berntorp, E.
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, SE-75124 Uppsala, Sweden
[2] Malmo Univ Hosp, Hosp Pharm, Malmo, Sweden
[3] Lund Univ, Dept Coagulat Disorders, Malmo Univ Hosp, Malmo, Sweden
关键词
dosing; factor VIII; factor IX; in vivo recovery; pharmacokinetics; variance;
D O I
10.1111/j.1365-2516.2006.01401.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In vivo recovery IVR) is traditionally used as a parameter to characterize the pharmacokinetic properties of coagulation factors. It has also been suggested that dosing of factor VIII (FVIII) and factor IX (FIX) can be adjusted according to the need of the individual patient, based on an individually determined IVR value. This approach, however, requires that the individual IVR value is more reliably representative for the patient than the mean value in the population, i.e. that there is less variance within than between the individuals. The aim of this investigation was to compare intra- and interindividual variance in TVR (as U dL(-1) per U kg(-1)) for FVIII and plasma-derived FIX in a cohort of nonbleeding patients with haemophilia. The data were collected retrospectively from six clinical studies, yielding 297 IVR determinations in 50 patients with haemophilia A and 93 determinations in 13 patients with haemophilia B. For FVIII, the mean variance within patients exceeded the between-patient variance. Thus, an individually determined IVR value is apparently no more informative than an average, or population, value for the dosing of FVIII. There was no apparent relationship between IVR and age of the patient (1.5-67 years). For FIX, the mean variance within patients was lower than the between-patient variance, and there was a significant positive relationship between IVR and age (13-69 years). From these data, it seems probable that using an individual IVR confers little advantage in comparison to using an age-specific population mean value. Dose tailoring of coagulation factor treatment has been applied successfully after determination of the entire single-dose curve of FVIII:C or FIX:C in the patient and calculation of the relevant pharmacokinetic parameters. However, the findings presented here do not support the assumption that dosing of FVIII or FIX can be individualized on the basis of a clinically determined IVR value.
引用
收藏
页码:2 / 8
页数:7
相关论文
共 23 条
[1]   A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia [J].
Ahnström, J ;
Berntorp, E ;
Lindvall, K ;
Björkman, S .
HAEMOPHILIA, 2004, 10 (06) :689-697
[2]   EFFECT OF HEIGHT AND WEIGHT ON THE INVIVO RECOVERY OF TRANSFUSED FACTOR-VIII-C [J].
ARONSTAM, A ;
MCLELLAN, DS ;
WASSEF, M ;
MBATHA, PS .
JOURNAL OF CLINICAL PATHOLOGY, 1982, 35 (03) :289-291
[3]  
BERNTORP E, 1993, THROMB HAEMOSTASIS, V70, P768
[4]   Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective [J].
Björkman, S .
HAEMOPHILIA, 2003, 9 :101-108
[5]   Pharmacokinetics of recombinant factor IX in relation to age of the patient:: implications for dosing in prophylaxis [J].
Björkman, S ;
Shapiro, AD ;
Berntorp, E .
HAEMOPHILIA, 2001, 7 (02) :133-139
[6]  
Björkman S, 2001, CLIN PHARMACOKINET, V40, P815
[7]  
BJORKMAN S, 1992, CLIN PHARMACOKINET, V22, P385
[8]  
BJORKMAN S, 1994, EUR J CLIN PHARMACOL, V46, P325
[9]   Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A [J].
Carlsson, M ;
Berntorp, E ;
Bjorkman, S ;
Lethagen, S ;
Ljung, R .
HAEMOPHILIA, 1997, 3 (02) :96-101
[10]  
Carlsson M, 1998, HAEMOPHILIA, V4, P83